Live Breaking News & Updates on Affinity asset advisors

Stay informed with the latest breaking news from Affinity asset advisors on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Affinity asset advisors and stay connected to the pulse of your community

Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Price Target at $6.29

Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Price Target at $6.29
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Robertw-baird , Merck-kga , Merck-kgaa , Affinity-asset-advisors , Newtyn-management , Mersana-therapeutics-inc , Jpmorgan-chase-co , Mersana-therapeutics-company-profile , Janssen-biotech-inc , Nasdaq , Asana-biosciences

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from Brokerages

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Mark-mcdade , Capital-management , Tourmaline-bio-inc , Denali-advisors , Affinity-asset-advisors , Jump-financial , Securities-exchange-commission , Jefferies-financial-group , Nasdaq , Tourmaline-bio , Get-free-report , Financial-group

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 3.6%

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report)’s stock price traded down 3.6% during mid-day trading on Wednesday . The stock traded as low as $3.24 and last traded at $3.25. 110,132 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 2,523,398 shares. The stock had previously closed […]

Canada , Nasdaq , Jpmorgan-chase-co , Caxton-associates , Royal-bank , Bourgeon-capital-management , Affinity-asset-advisors , Allogene-therapeutics-inc , Allogene-therapeutics , Get-free-report , Therapeutics-stock-down

Cullinan Oncology (NASDAQ:CGEM) Trading 7.8% Higher

Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report)’s stock price shot up 7.8% on Wednesday . The stock traded as high as $18.24 and last traded at $17.97. 153,899 shares were traded during trading, a decline of 68% from the average session volume of 477,343 shares. The stock had previously closed at $16.67. Wall Street […]

United-states , William-blair , Corrine-savill , Cullinan-oncology-inc , Franklin-resources-inc , Cullinan-oncology-company-profile , Affinity-asset-advisors , Securities-exchange-commission , Quest-partners , Nasdaq , Parkman-healthcare-partners , Investment-management

Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Rating of "Buy" by Analysts

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last […]

Mark-mcdade , Jefferies-financial-group , Nasdaq , Capital-management , Denali-advisors , Affinity-asset-advisors , Tourmaline-bio-inc , Jump-financial , Tourmaline-bio , Get-free-report , Financial-group , Truist-financial

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $61.80 Average Target Price from Brokerages

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has received a consensus rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued a report on the stock […]

Mark-mcdade , Jefferies-financial-group , Nasdaq , Capital-management , Denali-advisors , Affinity-asset-advisors , Tourmaline-bio-company-profile , Tourmaline-bio-inc , Securities-exchange-commission , Jump-financial , Tourmaline-bio , Get-free-report

NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Up 6.7%

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report)’s share price rose 6.7% during trading on Tuesday . The company traded as high as $21.78 and last traded at $21.58. Approximately 22,961 shares changed hands during trading, a decline of 90% from the average daily volume of 240,353 shares. The stock had previously closed at $20.23. Analyst […]

Canada , Jamesn-topper , Piper-sandler , Newamsterdam-pharma , Louisg-lange , Newamsterdam-pharma-company , Wolverine-asset-management , Newamsterdam-pharma-company-profile , Securities-exchange-commission , Opaleye-management-inc , Royal-bank , Schonfeld-strategic-advisors

Astria Therapeutics (NASDAQ:ATXS) Trading Down 2.9% on Analyst Downgrade

Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report)’s stock price was down 2.9% during mid-day trading on Tuesday after HC Wainwright lowered their price target on the stock from $18.00 to $16.00. HC Wainwright currently has a buy rating on the stock. Astria Therapeutics traded as low as $9.51 and last traded at $9.52. Approximately […]

United-states , Christopher-morabito , Capital-management , Perceptive-advisors-llc , Jump-financial , Armistice-capital , Jefferies-financial-group , Affinity-asset-advisors , Nasdaq , Astria-therapeutics-inc , Perceptive-advisors , Astria-therapeutics

COMPASS Pathways' (CMPS) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

COMPASS Pathways (NASDAQ:CMPS – Get Free Report)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga reports. Other equities research analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 target price on shares […]

United-kingdom , United-states , George-jay-goldsmith , Ekaterina-malievskaia , Affinity-asset-advisors , Vivo-capital , Pathways-company-profile , Investment-management , Cantor-fitzgerald , Securities-exchange-commission , Morgan-stanley , Get-free-report

Cantor Fitzgerald Reaffirms "Overweight" Rating for Vincerx Pharma (NASDAQ:VINC)

Cantor Fitzgerald restated their overweight rating on shares of Vincerx Pharma (NASDAQ:VINC – Free Report) in a research report released on Tuesday morning, Benzinga reports. Vincerx Pharma Stock Performance Shares of VINC opened at $0.98 on Tuesday. The stock has a market cap of $20.98 million, a PE ratio of -0.52 and a beta of […]

Montreal , Quebec , Canada , United-states , Vincerx-pharma , Vanguard-group-inc , Vincerx-pharma-inc , Renaissance-technologies , Cantor-fitzgerald , Affinity-asset-advisors , Free-report , Montreal-can